Bayer and Recursion focus research collaboration on Oncology
Digitally enabled drug discovery for oncology with potential to accelerate the delivery of new cancer therapies to patients
Digitally enabled drug discovery for oncology with potential to accelerate the delivery of new cancer therapies to patients
he company posted total income during Q2 FY24 at Rs. 12.86 crore
This collaboration underscores WOTR's unwavering commitment to strengthening rural communities against the unpredictable variations of climate change
Dr. Reddy’s maintains that the allegations against it lack merit and will vigorously defend the litigation
The collaboration brings a seamless digital experience to more formulators worldwide
We are redesigning Bayer to focus only on what’s essential for our mission, ‘Health for all, hunger for none’”
Total transaction value of the divestment is Rs. 3,660 million
Lack of technology transfer stands out as a formidable barrier
This product will be manufactured at Lupin’s Pithampur facility in India
Subscribe To Our Newsletter & Stay Updated